Advice
Following a full submission.
Vinorelbine capsule (NavelbineP®POral) is accepted for restricted use within NHS Scotland for the first line treatment of stage lll or lV non-small-cell lung cancer. It is restricted to use by specialist oncologists as an alternative to the intravenous formulation of vinorelbine. It is more expensive than the intravenous formulation of vinorelbine. However, its use may allow changes to service delivery that have individual patient or organisational benefits
Download detailed advice73KB (PDF)
Medicine details
- Medicine name:
- Vinorelbine capsule (Navelbine Oral®)
- SMC ID:
- 179/05
- Indication:
- Stage lll or lV non-small-cell lung cancer
- Pharmaceutical company
- Pierre Fabre Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 June 2005